JP2001514749A - Hiv抗原及びhiv抗体の同時決定方法 - Google Patents
Hiv抗原及びhiv抗体の同時決定方法Info
- Publication number
- JP2001514749A JP2001514749A JP53917798A JP53917798A JP2001514749A JP 2001514749 A JP2001514749 A JP 2001514749A JP 53917798 A JP53917798 A JP 53917798A JP 53917798 A JP53917798 A JP 53917798A JP 2001514749 A JP2001514749 A JP 2001514749A
- Authority
- JP
- Japan
- Prior art keywords
- hiv1
- antigen
- binding
- subo
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 206
- 108091007433 antigens Proteins 0.000 title claims abstract description 206
- 102000036639 antigens Human genes 0.000 title claims abstract description 206
- 238000000034 method Methods 0.000 title claims abstract description 63
- 101710147327 Calcineurin B homologous protein 1 Proteins 0.000 claims abstract description 201
- 101710205625 Capsid protein p24 Proteins 0.000 claims abstract description 201
- 101710177166 Phosphoprotein Proteins 0.000 claims abstract description 201
- 101710149279 Small delta antigen Proteins 0.000 claims abstract description 201
- 102100031987 Transmembrane emp24 domain-containing protein 2 Human genes 0.000 claims abstract description 201
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims abstract description 139
- 101710072850 Poxin Proteins 0.000 claims abstract description 41
- 101710142282 Protein P26 Proteins 0.000 claims abstract description 41
- 102100032106 Transmembrane emp24 domain-containing protein 3 Human genes 0.000 claims abstract description 41
- 208000031886 HIV Infections Diseases 0.000 claims abstract description 29
- 208000037357 HIV infectious disease Diseases 0.000 claims abstract description 26
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims abstract description 26
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 14
- 238000003018 immunoassay Methods 0.000 claims abstract description 13
- 238000002405 diagnostic procedure Methods 0.000 claims abstract description 9
- 238000011895 specific detection Methods 0.000 claims abstract description 5
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims abstract 27
- 230000027455 binding Effects 0.000 claims description 106
- 239000007790 solid phase Substances 0.000 claims description 59
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 43
- 238000001514 detection method Methods 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 22
- 208000015181 infectious disease Diseases 0.000 claims description 13
- 239000000654 additive Substances 0.000 claims description 9
- 238000005259 measurement Methods 0.000 claims description 8
- 239000012071 phase Substances 0.000 claims description 8
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 claims description 7
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 claims description 2
- 238000012360 testing method Methods 0.000 abstract description 82
- 230000008569 process Effects 0.000 abstract description 3
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 108020003175 receptors Proteins 0.000 description 150
- 102000005962 receptors Human genes 0.000 description 150
- 108090000765 processed proteins & peptides Proteins 0.000 description 32
- 102100034353 Integrase Human genes 0.000 description 28
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 23
- 230000009870 specific binding Effects 0.000 description 20
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 19
- 101800000385 Transmembrane protein Proteins 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 13
- 238000013507 mapping Methods 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 10
- 239000012634 fragment Substances 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 101710090322 Truncated surface protein Proteins 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000007791 liquid phase Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 108010089520 pol Gene Products Proteins 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 208000030507 AIDS Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 235000020958 biotin Nutrition 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000560067 HIV-1 group M Species 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical group C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 108700004025 env Genes Proteins 0.000 description 4
- 101150030339 env gene Proteins 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102100021334 Bcl-2-related protein A1 Human genes 0.000 description 3
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 3
- -1 HIV2 About gp140 Proteins 0.000 description 3
- 101000677540 Homo sapiens Acetyl-CoA carboxylase 2 Proteins 0.000 description 3
- 101000894929 Homo sapiens Bcl-2-related protein A1 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 3
- 108010078428 env Gene Products Proteins 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 239000000941 radioactive substance Substances 0.000 description 3
- 238000003118 sandwich ELISA Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 2
- 101710177291 Gag polyprotein Proteins 0.000 description 2
- 101710114816 Gene 41 protein Proteins 0.000 description 2
- 101000719019 Homo sapiens Glutamyl aminopeptidase Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 108010061833 Integrases Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 108700004029 pol Genes Proteins 0.000 description 2
- 101150088264 pol gene Proteins 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 1
- IITIZHOBOIBGBW-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole Chemical compound C1=CC=C2N(CC)CSC2=C1 IITIZHOBOIBGBW-UHFFFAOYSA-N 0.000 description 1
- RZLZXKPCGOYHPS-UHFFFAOYSA-N 3h-dithiole;ethanol Chemical compound CCO.C1SSC=C1 RZLZXKPCGOYHPS-UHFFFAOYSA-N 0.000 description 1
- QTEVNHAXZBQTKS-CAGKOAJJSA-N 5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid 3-(5-aminohexanoyl)-1-hydroxypyrrolidine-2,5-dione Chemical compound NC(CCCC(=O)C1C(=O)N(C(C1)=O)O)C.OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12 QTEVNHAXZBQTKS-CAGKOAJJSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000029483 Acquired immunodeficiency Diseases 0.000 description 1
- 241001385733 Aesculus indica Species 0.000 description 1
- 244000105975 Antidesma platyphyllum Species 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 241001669573 Galeorhinus galeus Species 0.000 description 1
- 108010027044 HIV Core Protein p24 Proteins 0.000 description 1
- 208000007521 HIV Seropositivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001745 anti-biotin effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001615 biotins Chemical class 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005101 cell tropism Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000009424 haa Nutrition 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000001038 ionspray mass spectrometry Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- JKRHDMPWBFBQDZ-UHFFFAOYSA-N n'-hexylmethanediimine Chemical compound CCCCCCN=C=N JKRHDMPWBFBQDZ-UHFFFAOYSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 101150080184 p17 gene Proteins 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 239000013034 phenoxy resin Substances 0.000 description 1
- 229920006287 phenoxy resin Polymers 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 150000003303 ruthenium Chemical class 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 229960001922 sodium perborate Drugs 0.000 description 1
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1054—Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- AIDS & HIV (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. HIV1、HIV1−SubOのp24抗原及び/又はHIV2のp26 抗原、HIV1、HIV1−SubO及び/又はHIV2のenv領域に対する 少なくとも1種類の抗体、並びにHIV1、HIV1−SubO及び/又はHI V2のpol及び/又はgag領域に対する少なくとも1種類の抗体の特異的検 出を用いるイムノアッセイによりHIV感染を診断するための方法。 2. HIV感染の検出を不均一イムノアッセイにより行う、請求項1記載の方 法。 3. 検出のために、HIV1、HIV1−SubOのp24抗原及び/又はH IV2のp26抗原に特異的に結合でき、かつ固相に結合しているか又はそれに 結合するのに適する少なくとも1種類の受容体R1、 HIV1、HIV1−SubOのp24抗原及び/又はHIV2のp26抗原 に特異的に結合するのに適し、かつ標識を有する少なくとも1種類の受容体R2 、ここで、R1及びR2により認識されるエピトープは異なるものである、 env領域に由来する抗原に対する、測定しようとするHIV1、HIV1− SubO及び/又はHIV2抗体に特異的に結合するのに適し、かつ固相に結合 しているか又はそれに結合するのに適する少なくとも1種類の受容体R3、 env領域に由来する抗原に対する、測定しようとするHIV1、HIV1− SubO及び/又はHIV2抗体に特異的に結合するのに適し、かつ標識を有す る少なくとも1種類の受容体R4、 pol又はgag領域に由来する抗原に対する、測定しようとするHIV1、 HIV1−SubO及び/又はHIV2抗体に特異的に結合するのに適し、かつ 固相に結合しているか又はそれに結合するのに適する少なくとも1種類の受容体 R5、及び pol又はgag領域に由来する抗原に対する、測定しようとするHIV1、 HIV1−SubO及び/又はHIV2抗体に特異的に結合するのに適し、かつ 標識を有する少なくとも1種類の受容体R6を用い、必要により液相から固相を 分離して該2つの相のうちの一方で標識の測定を行う、請求項1又は2記載の方 法。 4. 受容体R1及びR2がHIV1のp24抗原に特異的に結合でき、受容体 R3及びR4がenv領域の抗原に対する、測定しようとするHIV1抗体に特 異的に結合でき、かつ受容体R5及びR6がgag又はpol領域の抗原に対す る、測定しようとするHIV1抗体に特異的に結合できる、請求項2又は3記載 の方法。 5. 受容体R5及びR6がpol領域の抗原に対する、測定しようとするHI V1抗体に特異的に結合できる、請求項3又は4記載の方法。 6. 受容体R5及びR6がHIV逆転写酵素に対する抗体に特異的に結合でき る、請求項3〜5のいずれかに記載の方法。 7. 受容体R5及びR6がgag−p17抗原に対する抗体に特異的に結合で きる、請求項3〜5のいずれかに記載の方法。 8. HIV1−SubOの感染も検出される、請求項1〜7のいずれかに記載 の方法。 9. グループMの全てのHIV1サブタイプの感染も検出される、請求項1〜 8のいずれかに記載の方法。 10. 受容体R1及びR2が、各々、HIV1、HIV1−SubOのp24 抗原の異なるエピトープ及び/又はHIV2のp26抗原の異なるエピトープを 認識する幾つかの受容体の混合物である、請求項1〜9のいずれかに記載の方法 。 11. HIVに対する抗体を検出するための方法であって、 env領域に由来する抗原に対する、測定しようとするHIV1、HIV1− SubO及び/又はHIV2抗体に特異的に結合するのに適し、かつ固相に結合 しているか又はそれに結合するのに適する少なくとも1種類の受容体R3、 env領域に由来する抗原に対する、測定しようとするHIV1、HIV1− SubO及び/又はHIV2抗体に特異的に結合するのに適し、かつ標識を有す る少なくとも1種類の受容体R4、 pol又はgag領域に由来する抗原に対する、測定しようとするHIV1、 HIV1−SubO及び/又はHIV2抗体に特異的に結合するのに適し、かつ 固相に結合しているか又はそれに結合するのに適する少なくとも1種類の受容体 R5、及び pol又はgag領域に由来する抗原に対する、測定しようとするHIV1、 HIV1−SubO及び/又はHIV2抗体に特異的に結合するのに適し、かつ 標識を有する少なくとも1種類の受容体R6を用い、必要により液相から固相を 分離して該2つの相のうちの一方で標識の測定を行う、前記方法。 12. 配列番号1〜36記載のp24エピトープに特異的に結合する、HIV 1 p24抗原に対するモノクローナル抗体。 13. 配列番号3、9、17、31又は34記載のp24エピトープに特異的 に結合する、HIV1 p24抗原に対するモノクローナル抗体。 14. 細胞系mAb<p24>M−6A9/5(寄託番号DSM ACC23 10)、mAb<p24>M−4B1/1(寄託番号DSM ACC2299)、 mAb<p24>M−6D9/4(寄託番号DSM ACC2300)又はmA b<p24>M−2E7/3(寄託番号DSM ACC2301)から産生され る、HIV1 p24抗原に対するモノクローナル抗体。 15. 細胞系mAb<p24>M−6A9/5(DSM ACC2310)、m Ab<p24>M−4B1/1(DSM ACC2299)、mAb<p24>M −6D9/4(DSM ACC2300)又はmAb<p24>M−2E7/3 (DSM ACC2301)から産生されるモノクローナル抗体と同じ様式でp 24に結合する、HIV1 p24抗原に対するモノクローナル抗体。 16. 細胞系mAb<p24>M−6A9/5(DSM ACC2310)、m Ab<p24>M−4B1/1(DSM ACC2299)、mAb<p24>M −6D9/4(DSM ACC2300)又はmAb<p24>M−2E7/3 (DSM ACC2301)から産生されるモノクローナル抗体と同じエピトー プに結合する、HIV1 p24抗原に対するモノクローナル抗体。 17. HIV感染を検出するための診断試験における、請求項12〜16のい ずれかに記載の少なくとも1種類のモノクローナル抗体の使用。 18. HIV感染を検出するための、請求項1〜10記載の方法の診断試験に おける、請求項12〜16のいずれかに記載の少なくとも1種類のモノクローナ ル抗体の使用。 19. HIV感染を検出するための試薬キットであって、 HIV1、HIV1−SubOのp24抗原及び/又はHIV2のp26抗原 に特異的に結合するのに適し、かつ固相に結合しているか又はそれに結合するの に適する少なくとも1種類の受容体R1、 HIV1、HIV1−SubOのp24抗原及び/又はHIV2のp26抗原 に特異的に結合するのに適し、かつ標識を有する少なくとも1種類の受容体R2 、ここで、R1及びR2により認識されるエピトープは異なるものである、 env領域に由来する抗原に対する、測定しようとするHIV1、HIV1− SubO及び/又はHIV2抗体に特異的に結合するのに適し、かつ固相に結合 しているか又はそれに結合するのに適する少なくとも1種類の受容体R3、 env領域に由来する抗原に対する、測定しようとするHIV1、HIV1− SubO及び/又はHIV2抗体に結合するのに適し、かつ標識を有する少なく とも1種類の受容体R4、 pol又はgag領域に由来する抗原に対する、測定しようとするHIV1、 HIV1−SubO及び/又はHIV2抗体に結合するのに適し、かつ固相に結 合しているか又はそれに結合するのに適する少なくとも1種類の受容体R5、及 び pol又はgag領域に由来する抗原に対する、測定しようとするHIV1、 HIV1−SubO及び/又はHIV2抗体に特異的に結合するのに適し、かつ 標識を有する少なくとも1種類の受容体R6を含み、これらに加えて必要であれ ば他の通常の添加物を含む、試薬キット。 20. 細胞系mAb<p24>M−6A9/5(DSM ACC2310)、m Ab<p24>M−4B1/1(DSM ACC2299)、mAb<p24>M −6D9/4(DSM ACC2300)又はmAb<p24>M−2E7/3 (DSM ACC2301)から産生される抗体を受容体R1及びR2として用 いる、請求項19記載の試薬キット。 21. HIV1、HIV1−SubOのp24抗原及び/又はHIV2のp2 6抗原に特異的に結合するのに適し、かつ固相に結合しているか又はそれに結合 するのに適する少なくとも1種類の受容体R1、 HIV1、HIV1−SubOのp24抗原及び/又はHIV2のp26抗原 に特異的に結合するのに適し、かつ標識を有する少なくとも1種類の受容体R2 、ここで、R1及びR2により認識されるエピトープは異なるものである、 env領域に由来する抗原に対する、測定しようとするHIV1、HIV1− SubO及び/又はHIV2抗体に特異的に結合するのに適し、かつ固相に結合 しているか又はそれに結合するのに適する少なくとも1種類の受容体R3、 env領域に由来する抗原に対する、測定しようとするHIV1、HIV1− SubO及び/又はHIV2抗体に特異的に結合するのに適し、かつ標識を有す る少なくとも1種類の受容体R4、 pol又はgag領域に由来する抗原に対する、測定しようとするHIV1、 HIV1−SubO及び/又はHIV2抗体に特異的に結合するのに適し、かつ 固相に結合しているか又はそれに結合するのに適する少なくとも1種類の受容体 R5、及び pol又はgag領域に由来する抗原に対する、測定しようとするHIV1、 HIV1−SubO及び/又はHIV2抗体に特異的に結合するのに適し、かつ 標識を有する少なくとも1種類の受容体R6を含み、これらに加えて必要であれ ば他の通常の添加剤を含む、試験片。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19709762 | 1997-03-10 | ||
DE19727943.0 | 1997-07-01 | ||
DE19727943A DE19727943A1 (de) | 1997-03-10 | 1997-07-01 | Verfahren zur simultanen Bestimmung von HIV-Antigenen und HIV-Antikörpern |
DE19709762.6 | 1997-07-01 | ||
PCT/EP1998/001235 WO1998040744A1 (de) | 1997-03-10 | 1998-03-05 | Verfahren zur simultanen bestimmung von hiv-antigenen und hiv-antikörpern |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001514749A true JP2001514749A (ja) | 2001-09-11 |
JP3534417B2 JP3534417B2 (ja) | 2004-06-07 |
Family
ID=26034683
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53917798A Expired - Lifetime JP3534417B2 (ja) | 1997-03-10 | 1998-03-05 | Hiv抗原及びhiv抗体の同時決定方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US6593079B1 (ja) |
EP (1) | EP0972198B2 (ja) |
JP (1) | JP3534417B2 (ja) |
AT (1) | ATE228248T1 (ja) |
AU (1) | AU6727798A (ja) |
CA (1) | CA2283058C (ja) |
ES (1) | ES2187947T5 (ja) |
WO (1) | WO1998040744A1 (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO311807B1 (no) * | 1999-03-04 | 2002-01-28 | Bionor Immuno As | HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV |
AU2004200155C1 (en) * | 1999-03-04 | 2015-07-23 | Bionor Immuno As | HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV |
DE10059720A1 (de) | 2000-11-30 | 2002-06-06 | Roche Diagnostics Gmbh | Verwendung intramolekular kovalent vernetzter Proteine als Bindepartner in Immunoassays |
US6818392B2 (en) * | 2000-12-06 | 2004-11-16 | Abbott Laboratories | Monoclonal antibodies to human immunodeficiency virus and uses thereof |
FR2839555B1 (fr) | 2002-05-10 | 2007-07-27 | Bio Rad Pasteur | Procede de detection simultanee d'un antigene et d'un anticorps d'un microorganisme infectieux |
FR2882557A1 (fr) * | 2005-02-25 | 2006-09-01 | Centre Nat Rech Scient | Epitopes de vih et composition pharmaceutique les contenant |
US8324153B2 (en) | 2008-05-06 | 2012-12-04 | New York Blood Center, Inc. | Antiviral cell-penetrating peptides |
US8937154B2 (en) | 2006-10-05 | 2015-01-20 | New York Blood Center, Inc. | Stabilized therapeutic small helical antiviral peptides |
EP1933145B1 (en) * | 2006-12-11 | 2011-09-28 | AraGen Biotechnology Co. Ltd. | Rapid immunochromatographic detection by amplification of the colloidal gold signal |
US20100297607A1 (en) | 2009-05-20 | 2010-11-25 | Jian Zheng | Reagents For HCV Antigen-Antibody Combination Assays |
EP2550362B1 (en) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
PT2691530T (pt) | 2011-06-10 | 2018-05-10 | Univ Oregon Health & Science | Glicoproteínas e vectores recombinantes cmv |
US20130189754A1 (en) | 2011-09-12 | 2013-07-25 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3445816C1 (de) | 1984-12-15 | 1986-06-12 | Behringwerke Ag, 3550 Marburg | Flaechenfoermiges diagnostisches Mittel |
DE3636540A1 (de) | 1986-10-27 | 1988-04-28 | Behringwerke Ag | Verfahren zur bestimmung von anti-hiv, mittel dazu und ihre verwendung in diesem verfahren |
DE3705686C2 (de) | 1987-02-23 | 1995-11-30 | Boehringer Mannheim Gmbh | Verfahren zur Bestimmung von Antikörpern |
EP1369427A3 (en) † | 1988-06-09 | 2004-05-12 | Innogenetics N.V. | HIV-3 retrovirus strains and their use |
EP0386713B1 (en) | 1989-03-09 | 1996-09-18 | Abbott Laboratories | Immunoassay for antibodies to HIV |
JP2001504572A (ja) * | 1992-04-09 | 2001-04-03 | アボツト・ラボラトリーズ | Hiv抗原及びhiv抗体を検出するためのアッセイ |
DE4236189A1 (de) | 1992-10-27 | 1994-04-28 | Boehringer Mannheim Gmbh | Verfahren zur simultanen Bestimmung von Antigenen und Antikörpern |
JP3604147B2 (ja) | 1994-07-25 | 2004-12-22 | ロシュ ダイアグノスティックス ゲーエムベーハー | 金属キレート標識ペプチド |
AU684992B2 (en) | 1994-07-25 | 1998-01-08 | Boehringer Mannheim Gmbh | Hapten-marked peptides |
CN1148578C (zh) | 1994-07-25 | 2004-05-05 | 罗切诊断学有限公司 | 免疫测定特异抗体的方法、所用试剂、抗原及其用途 |
-
1998
- 1998-03-05 WO PCT/EP1998/001235 patent/WO1998040744A1/de active IP Right Grant
- 1998-03-05 AT AT98912441T patent/ATE228248T1/de active
- 1998-03-05 ES ES98912441.7T patent/ES2187947T5/es not_active Expired - Lifetime
- 1998-03-05 EP EP98912441.7A patent/EP0972198B2/de not_active Expired - Lifetime
- 1998-03-05 CA CA2283058A patent/CA2283058C/en not_active Expired - Lifetime
- 1998-03-05 AU AU67277/98A patent/AU6727798A/en not_active Abandoned
- 1998-03-05 US US09/381,009 patent/US6593079B1/en not_active Expired - Lifetime
- 1998-03-05 JP JP53917798A patent/JP3534417B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO1998040744A1 (de) | 1998-09-17 |
EP0972198A1 (de) | 2000-01-19 |
ES2187947T5 (es) | 2014-01-29 |
AU6727798A (en) | 1998-09-29 |
ATE228248T1 (de) | 2002-12-15 |
EP0972198B1 (de) | 2002-11-20 |
CA2283058A1 (en) | 1998-09-17 |
CA2283058C (en) | 2011-09-27 |
JP3534417B2 (ja) | 2004-06-07 |
ES2187947T3 (es) | 2003-06-16 |
US6593079B1 (en) | 2003-07-15 |
EP0972198B2 (de) | 2013-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2733059B2 (ja) | Htlv−▲iii▼抗体の診断用ペプチド並びにそれらの製造法及び用途 | |
JP3534417B2 (ja) | Hiv抗原及びhiv抗体の同時決定方法 | |
JP3556228B2 (ja) | 複数の抗原を使用した特異的免疫グロブリンの測定 | |
JPH01500053A (ja) | Htlv−3に対する抗体の検出法 | |
JPH06510192A (ja) | 推定上のhcv e2/ns1蛋白に対するモノクローナル抗体およびその使用方法 | |
US20030129587A1 (en) | Antigen/antibody specificity exchanger | |
EP1328811B1 (en) | Hcv mosaic antigen composition | |
KR100240514B1 (ko) | 멀티머 항원을 사용하는 특이적 면역글로불린의 측정방법 | |
US6322964B1 (en) | Synthetic HIV-2 gag and env oligopeptides reactive with HIV-2 specific antibodies | |
CA1339363C (en) | Monoclonal antibodies to specific antigenic regions of the human immunodeficiency virus and methods for use | |
EP0284383B2 (en) | Synthetic antigens for the detection of aids-related disease caused by LAV-2 | |
JP6808178B2 (ja) | ヒトパルボウイルスb19抗原および抗体の同時検出方法及びキット | |
EP0962774B1 (en) | Detection of antibodies to FIV using ENV/GAG polypeptides | |
WO1995023973A2 (en) | Hiv immunoassay utilizing recombinant protein and synthetic peptide reagents | |
JPH10502165A (ja) | 合成ペプチド−改良イムノアッセイを使用する異なるhiv遺伝子型の検出 | |
Manocha et al. | Comparing modified and plain peptide linked enzyme immunosorbent assay (ELISA) for detection of human immunodeficiency virus type-1 (HIV-1) and type-2 (HIV-2) antibodies | |
JPH09507025A (ja) | HEV orf−2に対するモノクローナル抗体及びそれらを使用する方法 | |
Sibille et al. | Comparison of serological tests for the diagnosis of feline immunodeficiency virus infection of cats | |
JP2837669B2 (ja) | T−細胞リンパ趨行性ウイルス蛋白及びその分析 | |
EP0386713A2 (en) | Immunoassay for antibodies to HIV | |
KR960013600B1 (ko) | 면역분석법에 이용되는 시스테인 티올-보호 펩티드 | |
US20040005548A1 (en) | Anti-HIV1 antibodies | |
JPH06510988A (ja) | 合成ペプチドを用いてのhtlv−1とhtlv−2との区別 | |
JPH04505621A (ja) | Tリンパ球向性レトロウイルス単クローン抗体 | |
JPH1072498A (ja) | 対照サンプルとしての抗hiv抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040210 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040309 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080319 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090319 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100319 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100319 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110319 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130319 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140319 Year of fee payment: 10 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |